Drug–Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer

Ipatasertib is a selective, small molecule Akt inhibitor that is currently being developed for the treatment of metastatic castration-resistant prostate cancer. Darolutamide is an androgen receptor (AR) inhibitor that is approved for the treatment of non-metastatic castration-resistant prostate canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sutaria, Dhruvitkumar S., Rasuo, Grozdana, Harris, Adam, Johnson, Ryan, Miles, Dale, Gallo, Jorge Daniel, Sane, Rucha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607266/
https://www.ncbi.nlm.nih.gov/pubmed/36297536
http://dx.doi.org/10.3390/pharmaceutics14102101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607266/
https://www.ncbi.nlm.nih.gov/pubmed/36297536
http://dx.doi.org/10.3390/pharmaceutics14102101

Ejemplares similares